Peer-influenced content. Sources you trust. No registration required. This is HCN.
JAMA Network
In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma.
Hematology May 25th 2020
Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS